Copy Link Print Information

Iptacopan TFA

(Synonyms: LNP023 TFA)
13 Cited Publications
Revisión del cliente

Based on 13 publication(s) in Google Scholar

Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).

Para uso exclusivo en investigación. No vendemos a pacientes.

  • No. CAS: 1644670-38-1
  • Fòrmula: C27H31F3N2O6
  • Peso molecular:536.55
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Iptacopan TFA Chemical Structure
    Iptacopan TFA Chemical Structure
  • Experimental Validation Results for Iptacopan TFA
  • Experimental Validation Results for Iptacopan TFA
  • Experimental Validation Results for Iptacopan TFA
  • Experimental Validation Results for Iptacopan TFA
  • Experimental Validation Results for Iptacopan TFA
No. CAS: 1644670-38-1
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Iptacopan TFA:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Iptacopan TFA

More
Customer Validation & Images
In Vivo Efficacy StudyIn Vivo ImagingWBBio/Physico-chemical Assay
  • WB
  • Bio/Physico-chemical Assay
  • In Vivo Efficacy Study
  • In Vivo Imaging
  • In Vivo Efficacy Study
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Iptacopan TFA Chemical Structure
    Iptacopan TFA Chemical Structure
    1/16
  • 1/16

    Iptacopan TFA purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2025 Dec;17(1):2484386. [Abstract]

    Customer Validation
     Western blot analysis of HIF-1α protein expression in M28-trained macrophages 3 days after inhibition of CFB (Iptacopan, 10 µM) or C3aR (SB290157, 10 µM). Data were presented as means ± SEM.

  • 1/16

    Iptacopan TFA purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2025 Dec;17(1):2484386. [Abstract]

    Customer Validation
     After pretreatment with the Iptacopan (CFB inhibitor) and SB290157 (C3aR inhibitor, 10 µM) for 24 hours, cells were treated with M28 (5 µg/mL) for an additional 24 hours. The cells were then washed twice with PBS to remove M28, and incubation was continued. 5 days later, macrophages were lysed to assess the phosphatidylcholine content. The results showed that, following treatment with the inhibitor, the phosphatidylcholine content within M28-trained macrophages decreased.

  • 1/16

    Iptacopan TFA purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2023 Oct 5;30(10):1315-1330.e10. [Abstract]

    Customer Validation
     Relative quantification of blood perfusion area in human vessels after Iptacopan (LNP023, 25 mg/kg; p.o.; 1 h before extracellular domain (ECD) injection) and spike-ECD or sham (ECD+DMSO) treatment to before treatment (mean ± SE; n = 3; Welch’s t-test; **p < 0.01). The results showed that LNP023 effectively inhibited thrombus formation in an engineered human vascular model.

  • 1/16

    Iptacopan TFA purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2023 Oct 5;30(10):1315-1330.e10. [Abstract]

    Customer Validation
     Intravital imaging of the organoid-transplanted mice treated with complement factor B inhibitor LNP023 and spike-ECD. Iptacopan (LNP023, 25 mg/kg; p.o) was orally administrated 1 hr before spike-ECD treatment. The organoid-derived human vascular and blood flow are visualized using a hCD31 and FITC-dextran, respectively.

  • 1/16

    Iptacopan TFA purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2022 Sep:153:113433. [Abstract]

    Customer Validation
     Iptacopan (LNP023, 30 mg/kg; gavage; once daily for 2 weeks) alleviated skin lesions, alopecia, and splenomegaly, effectively improving the lupus-like signs in MRL/lpr mice.

  • Iptacopan TFA